, Volume 47, Issue 6, pp 955–960 | Cite as

AE hepatic lesions: correlation between calcifications at CT and FDG-PET/CT metabolic activity

  • Eleonore Brumpt
  • Oleg Blagosklonov
  • Paul Calame
  • Solange Bresson-Hadni
  • Dominique Angèle Vuitton
  • Eric DelabrousseEmail author
Original Paper



To correlate the presence of calcifications in alveolar echinococcosis (AE) hepatic lesions to the metabolic activity in 18 fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT).


Our institutional review board approved this study. 61 patients (29 women, 32 men, aged from 15 to 86 years) were included in the study. Images of FDG-PET/CT were interpreted by two independent nuclear medicine physicians. AE hepatic lesions were classified as AE lesions with or without hypermetabolic activity. The presence of calcifications was assessed on unenhanced CT scans by two independent radiologists blinded with regard to the metabolic activity of the AE hepatic lesions. Every single calcification the size of which was < 3 mm and non-measurable calcifications which were forming areas with a powdery appearance were considered as microcalcifications. All other types of calcifications were reported as macrocalcifications. Statistical analysis was performed and p value < 0.05 was considered as statistically significant.


Microcalcifications and macrocalcifications were present at CT in 95% (58/61) AE hepatic lesions and 43% (26/61) AE hepatic lesions, respectively. Hypermetabolic activity was present at FDG-PET/CT in 93% (57/61) AE hepatic lesions. 98% (56/57) of the AE hepatic lesions presenting with hypermetabolic activity at FDG-PET/CT showed microcalcifications at CT (p = 0.01) when only 40% (23/57) showed macrocalcifications at CT (p = 0.3). 100% (23/23) of the AE hepatic lesions with hypermetabolic activity at FDG-PET/CT and macrocalcifications at CT showed also microcalcifications at CT.


Hypermetabolic activity of AE hepatic lesions at FDG-PET/CT is strongly correlated to the presence of microcalcifications at CT, independently of the presence of macrocalcifications.


Alveolar echinococcosis Calcifications FDG-PET/CT CT 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Kern P, Menezes da Silva A, Akhan O, Müllhaupt B, Vizcaychipi KA, Budke C, Vuitton DA. The Echinococcoses: diagnosis, clinical management and burden of disease. Adv Parasitol. 2017;96:259–369.CrossRefGoogle Scholar
  2. 2.
    Vuitton DA, Zhou H, Bresson-Hadni S, Wang Q, Piarroux M, Raoul F, Giraudoux P. Epidemiology of alveolar echinococcosis with particular reference to China and Europe. Parasitology. 2003;127(Suppl):S87–107.CrossRefGoogle Scholar
  3. 3.
    Brunetti E, Kern P, Vuitton DA. Writing Panel for the WHO-IWGE Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2010;114(1):1–16.CrossRefGoogle Scholar
  4. 4.
    Ammann RW, Stumpe KD, Grimm F, Deplazes P, Huber S, Bertogg K, Fischer DR, Müllhaupt B. Outcome after discontinuing long-term benzimidazole treatment in 11 patients with non-resectable Alveolar Echinococcosis with negative FDG-PET/CT and Anti-EmII/3-10 Serology. PLoS Negl Trop Dis. 2015;9(9):e0003964.CrossRefGoogle Scholar
  5. 5.
    Bardonnet K, Vuitton DA, Grenouillet F, Mantion GA, Delabrousse E, Blagosklonov O, Miguet JP, Bresson-Hadni S. 30-year course and favorable outcome of alveolar echinococcosis despite multiple metastatic organ involvement in a non-immune suppressed patient. Ann Clin Microbiol Antimicrob. 2013;2(12):1. Scholar
  6. 6.
    Bresson-Hadni S, Blagosklonov O, Knapp J, Grenouillet F, Sako Y, Delabrousse E, Brientini MP, Richou C, Minello A, Antonino AT, Gillet M, Ito A, Mantion GA, Vuitton DA. Should possible recurrence of disease contraindicate liver transplantation in patients with end-stage alveolar echinococcosis? A 20-year follow-up study. Liver Transpl. 2011;17(7):855–65.CrossRefGoogle Scholar
  7. 7.
    Liu W, Delabrousse É, Blagosklonov O, Wang J, Zeng H, Jiang Y, Wang J, Qin Y, Vuitton DA, Wen H. Innovation in hepatic alveolar echinococcosis imaging: best use of old tools, and necessary evaluation of new ones. Parasite. 2014;21:74.CrossRefGoogle Scholar
  8. 8.
    Bartholomot G, Vuitton DA, Harraga S, Shi DZ, Giraudoux P, Barnish G, Wang YH, MacPherson CN, Craig PS. Combined ultrasound and serologic screening for hepatic alveolar echinococcosis in central China. Am J Trop Med Hyg. 2002;66(1):23–9.CrossRefGoogle Scholar
  9. 9.
    Kantarci M, Bayraktutan U, Karabulut N, Aydinli B, Ogul H, Yuce I, Calik M, Eren S, Atamanalp SS, Oto A. Alveolar echinococcosis: spectrum of findings at cross-sectional imaging. Radiographics. 2012;32(7):2053–70.CrossRefGoogle Scholar
  10. 10.
    Reuter S, Kratzer W, Kurz S, Wellinghausen N, Kern P. Chemotherapy of alveolar echinococcosis with benzimidazoles. A prospective long-term study. Med Klin (Munich). 1998;93(8):463–7.CrossRefGoogle Scholar
  11. 11.
    Reuter S, Grüner B, Buck AK, Blumstein N, Kern P, Reske SN. Long-term follow-up of metabolic activity in human alveolar echinococcosis using FDG-PET. Nuklearmedizin. 2008;47(4):147–52.CrossRefGoogle Scholar
  12. 12.
    Azizi A, Blagosklonov O, Lounis A, Berthet L, Vuitton DA, Bresson-Hadni S, Delabrousse E. Alveolar echinococcosis: correlation between hepatic MRI findings and FDG-PET/CT metabolic activity. Abdom Imaging. 2015;40(1):56–63.CrossRefGoogle Scholar
  13. 13.
    Pittella JE. Pathology of CNS parasitic infections. Handb Clin Neurol. 2013;114:65–88.CrossRefGoogle Scholar
  14. 14.
    Graeter T, Kratzer W, Oeztuerk S, Haenle MM, Mason RA, Hillenbrand A, Kull T, Barth TF, Kern P, Gruener B. Proposal of a computed tomography classification for hepatic alveolar echinococcosis. World J Gastroenterol. 2016;22(13):3621–31.CrossRefGoogle Scholar
  15. 15.
    Charbonnier A, Knapp J, Demonmerot F, Bresson-Hadni S, Raoul F, Grenouillet F, Millon L, Vuitton DA, Damy S. A new data management system for the French National Registry of human alveolar echinococcosis cases. Parasite. 2014;21:69.CrossRefGoogle Scholar
  16. 16.
    Caoduro C, Porot C, Vuitton DA, Bresson-Hadni S, Grenouillet F, Richou C, Boulahdour H, Blagosklonov O. The role of delayed 18F-FDG PET imaging in the follow-up of patients with alveolar echinococcosis. J Nucl Med. 2013;54(3):358–63.CrossRefGoogle Scholar
  17. 17.
    Rausch RL, Wilson JF, Schantz PM, McMahon BJ. Spontaneous death of Echinococcus multilocularis: cases diagnosed serologically (by Em2 ELISA) and clinical significance. Am J Trop Med Hyg. 1987;36(3):576–85.CrossRefGoogle Scholar
  18. 18.
    Peng X, Li J, Wu X, Zhang S, Niu J, Chen X, Yao J, Sun H. Detection of Osteopontin in the pericyst of human hepatic Echinococcus granulosus. Acta Trop. 2006;100(3):163–71.CrossRefGoogle Scholar
  19. 19.
    O’Regan A, Berman JS. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol. 2000;81(6):373–90.CrossRefGoogle Scholar
  20. 20.
    Mueller J, Stojkovic M, Kauczor HU, Junghanss T, Weber TF. Performance of magnetic resonance susceptibility-weighted imaging for detection of calcifications in patients with hepatic echinococcosis. J Comput Assist Tomogr. 2018;42(2):211–5.PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Eleonore Brumpt
    • 1
  • Oleg Blagosklonov
    • 2
  • Paul Calame
    • 1
  • Solange Bresson-Hadni
    • 3
  • Dominique Angèle Vuitton
    • 3
  • Eric Delabrousse
    • 1
    • 3
    • 4
    Email author
  1. 1.Service de RadiologieCHU BesançonBesançonFrance
  2. 2.Service de Médecine NucléaireCHU BesançonBesançonFrance
  3. 3.WHO Collaborating Center for Prevention and Treatment of Human EchinococcosisBesançonFrance
  4. 4.EA 4662 Nanomedicine Lab, Imagery and TherapeuticsUniversité de Bourgogne Franche-ComtéBesançonFrance

Personalised recommendations